Physician profile
Steven E Freeman
NPI 1538290374
$10,261.32
in general payments reported to CMS, 2019-2025
57 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $842 · 2021: $1,851 · 2022: $2,333 · 2023: $1,780 · 2024: $1,407 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.58 | 2019-2025 | |
| Novo Nordisk INC | $1,125.68 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $858.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $701.62 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $628.03 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $598.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $541.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $479.42 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $326.46 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $311.76 | 2021-2023 | Glassia |
| Abbott Laboratories | $248.08 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $241.45 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceuticals, INC. | $218.94 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $175.17 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $169.37 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.